Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and petroleum products; and proprietary and joint industry studies. The Production Enhancement segment offers services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories N.V. was founded in 1936 and is based in Amstelveen, the Netherlands.
IPO Year: 2023
Exchange: NYSE
Website: corelab.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2025 | $15.00 → $16.00 | Sell → Neutral | Citigroup |
| 6/30/2023 | $22.00 → $21.00 | Neutral → Sell | Citigroup |
| 4/18/2023 | $21.50 | Neutral → Underperform | BofA Securities |
| 1/9/2023 | Underperform → Neutral | BofA Securities | |
| 10/7/2022 | $24.00 → $17.00 | Sell → Neutral | Citigroup |
| 9/26/2022 | $20.00 | Equal-Weight → Underweight | Morgan Stanley |
| 4/18/2022 | $19.50 → $21.30 | Neutral → Underweight | Piper Sandler |
| 1/18/2022 | $32.00 → $30.00 | Equal-Weight | Morgan Stanley |
| 12/7/2021 | $34.00 → $32.00 | Equal-Weight | Morgan Stanley |
| 10/18/2021 | $36.00 → $32.00 | Neutral → Underperform | BofA Securities |
3 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
4 - Core Laboratories Inc. /DE/ (0001958086) (Issuer)
REVENUE OF $130.2 MILLION, UP 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $15.3 MILLION; EX-ITEMS, $14.5 MILLION, UP OVER 23% SEQUENTIALLY AND DOWN 11% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF 11%, EXPANDED 160 BASIS POINTS SEQUENTIALLY, WITH INCREMENTAL MARGINS, EX-ITEMS, OF 41%GAAP EPS OF $0.22; EX-ITEMS, $0.19, UP 33% SEQUENTIALLY, AND DOWN 14% YEAR-OVER-YEARCOMPANY REPURCHASED 237,632 SHARES OF COMMON STOCK, A VALUE OF $2.7 MILLION FREE CASH FLOW OF $10.4 MILLION, UP OVER 160% SEQUENTIALLYNET DEBT REDUCED BY $9.1 MILLION; DEBT LEVERAGE RATIO IMPROVED TO 1.27 COMPANY ANNOUNCES Q2 2025 QUARTERLY DIVIDEND HOUSTON, July 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYS
HOUSTON, June 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on July 24, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 23, 2025, and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a replay a
HOUSTON, May 7, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") is pleased to announce the opening of its new Unconventional Core Analysis Laboratory in Dammam, Kingdom of Saudi Arabia. This state-of-the-art facility, developed in collaboration with Core's long-time partner, Abdulla Fouad Group, underscores the Company's commitment to advancing reservoir evaluation technologies in the Middle East. The Company's new analytical laboratory is equipped with advanced proprietary instrumentation designed to provide comprehensive core and fluid analysis services tailored to unconventional reservoirs. By bringing Core Lab's cutting-edge technologies t
REVENUE OF $123.6 MILLION, DOWN 4% SEQUENTIALLY AND 5% YEAR-OVER-YEAROPERATING INCOME OF $4.4 MILLION; EX-ITEMS, $11.8 MILLION, DOWN 25% SEQUENTIALLY AND 21% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF 10% GAAP EPS OF $0.00; EX-ITEMS, $0.14, DOWN 35% SEQUENTIALLY, AND 25% YEAR-OVER-YEARFREE CASH FLOW OF $3.9 MILLION, UP OVER 50% YEAR-OVER-YEAR NET DEBT REDUCED BY $4.9 MILLION; DEBT LEVERAGE RATIO REMAINS AT 1.31 COMPANY REPURCHASED 131,598 SHARES OF COMMON STOCK, A VALUE OF $2.0 MILLION COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDEND HOUSTON, April 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2025 revenue of $123,6
HOUSTON, March 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its first quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on April 24, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on April 23, 2025, and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a replay
FOURTH QUARTER REVENUE OF $129.2 MILLION, DOWN 4% SEQUENTIALLY AND UP SLIGHTLY YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $14.2 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 14% SEQUENTIALLY, UP 4% YEAR-OVER-YEAR FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.22, DOWN 12% SEQUENTIALLY, UP 16% YEAR-OVER-YEAR FOURTH QUARTER FREE CASH FLOW OF $16.2 MILLION, UP OVER 50% SEQUENTIALLY DEBT LEVERAGE RATIO REDUCED TO 1.31, AND NET DEBT REDUCED BY $11.7 MILLION COMPANY REPURCHASED 264,982 SHARES OF COMMON STOCK, A VALUE OF $4.9 MILLION, DURING THE FOURTH QUARTER COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $523.8 MILLION, UP 3%FULL
HOUSTON, Jan. 3, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2024 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on January 30, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on January 29, 2025 and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEARTHIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLYTHIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEARTHIRD QUARTER FREE CASH FLOW OF $10.4 MILLIONNET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDENDHOUSTON, Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's op
HOUSTON, Sept. 24, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its third quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on October 24, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on October 23rd and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a
SECOND QUARTER REVENUE OF $130.6 MILLION, UP SLIGHTLY SEQUENTIALLY AND YEAR-OVER-YEARSECOND QUARTER OPERATING INCOME OF $16.0 MILLION; EX-ITEMS, $16.4 MILLION, UP 10% SEQUENTIALLY AND 5% YEAR-OVER-YEAR SECOND QUARTER OPERATING MARGINS, EX-ITEMS, OF 13% SECOND QUARTER GAAP EPS OF $0.19; EX-ITEMS, $0.22, UP 16% SEQUENTIALLY AND 5% YEAR-OVER-YEARSECOND QUARTER FREE CASH FLOW OF $14.3 MILLION; NET DEBT REDUCED BY $15.8 MILLIONCOMPANY ANNOUNCES Q3 2024 QUARTERLY DIVIDENDHOUSTON, July 24, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2024 revenue of $130,600,000. Core's operating income was $16,000,000, with diluted earnin
10-Q - Core Laboratories Inc. /DE/ (0001958086) (Filer)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
11-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
SD - Core Laboratories Inc. /DE/ (0001958086) (Filer)
SCHEDULE 13G/A - Core Laboratories Inc. /DE/ (0001958086) (Subject)
10-Q - Core Laboratories Inc. /DE/ (0001958086) (Filer)
8-K - Core Laboratories Inc. /DE/ (0001958086) (Filer)
DEFA14A - Core Laboratories Inc. /DE/ (0001958086) (Filer)
Citigroup upgraded Core Labs from Sell to Neutral and set a new price target of $16.00 from $15.00 previously
Citigroup downgraded Core Labs from Neutral to Sell and set a new price target of $21.00 from $22.00 previously
BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $21.50
BofA Securities upgraded Core Labs from Underperform to Neutral
Citigroup upgraded Core Labs from Sell to Neutral and set a new price target of $17.00 from $24.00 previously
Morgan Stanley downgraded Core Labs from Equal-Weight to Underweight and set a new price target of $20.00
Piper Sandler downgraded Core Labs from Neutral to Underweight and set a new price target of $21.30 from $19.50 previously
Morgan Stanley reiterated coverage of Core Laboratories with a rating of Equal-Weight and set a new price target of $30.00 from $32.00 previously
Morgan Stanley reiterated coverage of Core Laboratories with a rating of Equal-Weight and set a new price target of $32.00 from $34.00 previously
BofA Securities downgraded Core Labs from Neutral to Underperform and set a new price target of $32.00 from $36.00 previously
REVENUE OF $130.2 MILLION, UP 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $15.3 MILLION; EX-ITEMS, $14.5 MILLION, UP OVER 23% SEQUENTIALLY AND DOWN 11% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF 11%, EXPANDED 160 BASIS POINTS SEQUENTIALLY, WITH INCREMENTAL MARGINS, EX-ITEMS, OF 41%GAAP EPS OF $0.22; EX-ITEMS, $0.19, UP 33% SEQUENTIALLY, AND DOWN 14% YEAR-OVER-YEARCOMPANY REPURCHASED 237,632 SHARES OF COMMON STOCK, A VALUE OF $2.7 MILLION FREE CASH FLOW OF $10.4 MILLION, UP OVER 160% SEQUENTIALLYNET DEBT REDUCED BY $9.1 MILLION; DEBT LEVERAGE RATIO IMPROVED TO 1.27 COMPANY ANNOUNCES Q2 2025 QUARTERLY DIVIDEND HOUSTON, July 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYS
HOUSTON, June 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on July 24, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 23, 2025, and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a replay a
REVENUE OF $123.6 MILLION, DOWN 4% SEQUENTIALLY AND 5% YEAR-OVER-YEAROPERATING INCOME OF $4.4 MILLION; EX-ITEMS, $11.8 MILLION, DOWN 25% SEQUENTIALLY AND 21% YEAR-OVER-YEAROPERATING MARGINS, EX-ITEMS, OF 10% GAAP EPS OF $0.00; EX-ITEMS, $0.14, DOWN 35% SEQUENTIALLY, AND 25% YEAR-OVER-YEARFREE CASH FLOW OF $3.9 MILLION, UP OVER 50% YEAR-OVER-YEAR NET DEBT REDUCED BY $4.9 MILLION; DEBT LEVERAGE RATIO REMAINS AT 1.31 COMPANY REPURCHASED 131,598 SHARES OF COMMON STOCK, A VALUE OF $2.0 MILLION COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDEND HOUSTON, April 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2025 revenue of $123,6
HOUSTON, March 24, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its first quarter 2025 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m. EST on April 24, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on April 23, 2025, and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a replay
FOURTH QUARTER REVENUE OF $129.2 MILLION, DOWN 4% SEQUENTIALLY AND UP SLIGHTLY YEAR-OVER-YEARFOURTH QUARTER OPERATING INCOME OF $14.2 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 14% SEQUENTIALLY, UP 4% YEAR-OVER-YEAR FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF 12% FOURTH QUARTER GAAP EPS OF $0.15; EX-ITEMS, $0.22, DOWN 12% SEQUENTIALLY, UP 16% YEAR-OVER-YEAR FOURTH QUARTER FREE CASH FLOW OF $16.2 MILLION, UP OVER 50% SEQUENTIALLY DEBT LEVERAGE RATIO REDUCED TO 1.31, AND NET DEBT REDUCED BY $11.7 MILLION COMPANY REPURCHASED 264,982 SHARES OF COMMON STOCK, A VALUE OF $4.9 MILLION, DURING THE FOURTH QUARTER COMPANY ANNOUNCES Q1 2025 QUARTERLY DIVIDENDFULL YEAR REVENUE OF $523.8 MILLION, UP 3%FULL
HOUSTON, Jan. 3, 2025 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its fourth quarter 2024 conference call for investors and analysts at 7:30 a.m. CST / 8:30 a.m. EST on January 30, 2025. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on January 29, 2025 and may be accessed through the Company's website at www.corelab.com. To register for the listen-only webcast, log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those not available to listen to the live webcast, a
THIRD QUARTER REVENUE OF $134.4 MILLION, UP 3% SEQUENTIALLY AND OVER 7% YEAR-OVER-YEARTHIRD QUARTER OPERATING INCOME OF $19.8 MILLION; EX-ITEMS, $18.2 MILLION, UP 11% SEQUENTIALLY AND 14% YEAR-OVER-YEAR THIRD QUARTER OPERATING MARGINS, EX-ITEMS, OF 14% UP 100 BPS SEQUENTIALLYTHIRD QUARTER GAAP EPS OF $0.25; EX-ITEMS, $0.25, UP 14% SEQUENTIALLY AND YEAR-OVER-YEARTHIRD QUARTER FREE CASH FLOW OF $10.4 MILLIONNET DEBT REDUCED BY $11.8 MILLION; DEBT LEVERAGE RATIO REDUCED TO 1.47COMPANY ANNOUNCES Q4 2024 QUARTERLY DIVIDENDHOUSTON, Oct. 23, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2024 revenue of $134,400,000. Core's op
HOUSTON, Sept. 24, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its third quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on October 24, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on October 23rd and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a
SECOND QUARTER REVENUE OF $130.6 MILLION, UP SLIGHTLY SEQUENTIALLY AND YEAR-OVER-YEARSECOND QUARTER OPERATING INCOME OF $16.0 MILLION; EX-ITEMS, $16.4 MILLION, UP 10% SEQUENTIALLY AND 5% YEAR-OVER-YEAR SECOND QUARTER OPERATING MARGINS, EX-ITEMS, OF 13% SECOND QUARTER GAAP EPS OF $0.19; EX-ITEMS, $0.22, UP 16% SEQUENTIALLY AND 5% YEAR-OVER-YEARSECOND QUARTER FREE CASH FLOW OF $14.3 MILLION; NET DEBT REDUCED BY $15.8 MILLIONCOMPANY ANNOUNCES Q3 2024 QUARTERLY DIVIDENDHOUSTON, July 24, 2024 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2024 revenue of $130,600,000. Core's operating income was $16,000,000, with diluted earnin
HOUSTON, June 25, 2024 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will broadcast its second quarter 2024 conference call over the Internet at 7:30 a.m. CDT / 8:30 a.m. EDT on July 25, 2024. Larry Bruno, Chairman and CEO, Chris Hill, CFO, and Gwen Gresham, SVP Corporate Development and Investor Relations, will discuss financial and operational results. An earnings press release will be issued after market close on July 24th and may be accessed through the Company's website at www.corelab.com. To participate in the live webcast, simply log on to www.corelab.com at least fifteen minutes prior to the start of the call. For those who are not available to listen to the live webcast, a Podcas
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)
SC 13G/A - CORE LABORATORIES N V (0001000229) (Subject)